Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | REN | P00797 | 5/20 | 0.46 |
| ▸ | MMP1 | P03956 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | MMP3 | P08254 | 2/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14899663 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL16463916 | 0.89 | KLK5 (0.53) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL16463914 | 0.89 | KLK5 (0.53) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL30196246 | 0.88 | ITGB3 (0.56) | ITGB3ITGA2BREN | |
| SCHEMBL16119245 | 0.85 | ITGB3 (0.46) | ITGB3ITGA2BMMP1CTSKMMP3 | |
| SCHEMBL16228287 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL12062761 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL16124030 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL16228288 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BRENMMP1CTSK | |
| SCHEMBL8091309 | 0.85 | ITGB3 (0.57) | ITGB3ITGA2BRENMMP1CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970224-B1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9657057-B2 | Dipeptide and tripeptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-02-04 | — | — | US | disclosed |
| WO-2014152134-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152127-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031934-A1 | DIPEPTIDE AND TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, PEPD, DNPEP | ITGB3 4753/4885ITGA2B 4803/4885REN 121/4885 |
| US-20160368946-A1 | TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, CTRL, ENPEP | ITGB3 4686/4885ITGA2B 4664/4885REN 155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.